INTRODUCTION
The insulin receptor and type I IGF receptor share many similarities of structure and function (reviewed by Czech, 1985; Rechler and Nissley, 1985; Humbel, 1990) , reflecting similarities in primary sequence (Ullrich et al., 1985 (Ullrich et al., , 1986 . Each receptor is synthesized as a single polypeptide and is proteolytically cleaved to give a-and fl-subunits, which are disulphide-linked in a ,-aa-,f configuration. The ligand-binding site is contained within the extracellular a-subunit (Yip et al., 1988; Wedekind et al., 1989; Kjeldsen et al., 1991; Schumacher et al., 1991) , and binding specificity is such that in spite of some cross-reaction each receptor should significantly bind only its own ligand at physiological concentrations (Humbel, 1990; Adamo et al., 1992) . The tyrosine kinase activity of the transmembrane fl-subunit, which is stimulated by ligand binding, is essential for intracellular signalling (reviewed by Zick, 1989; Olefsky, 1990) . The protein ppl85/IRS-1 is an endogenous substrate for both receptor tyrosine kinases (White et al., 1985; Izumi et al., 1987; Sun et al., 1991) , although the role of this protein and of other substrates in intracellular signalling remains unclear. The insulin receptor and type I IGF receptor mediate a similar range of biological effects in a given cell background (Shimizu et al., 1986; Steele-Perkins et al., 1988; Weiland et al., 1991) , although there is evidence that they differ in relative efficiency for initiating growth-promoting and acute metabolic actions (Lammers et al., 1989; Takata et al., 1991) .
In cells expressing both insulin receptors and type I IGF receptors, a proportion of the receptor a,f halves assemble as affinity-purified insulin receptors and type I IGF receptors, by using the radioligands '25I-IGF-I and 1251-insulin. Hybrids bound approx. 20 times as much 1251-IGF-I as 1251-insulin at tracer concentrations (approx. 0.1 nM). The binding of 1251-insulin, but not 1251-IGF-I, to hybrids increased after treatment with dithiothreitol to reduce disulphide bonds between the a-subunits. Hybrids behaved very similarly to type I receptors with respect to the inhibition of 1251-IGF-I binding by unlabelled IGF-I and insulin. By contrast, the affinity of hybrids for insulin was approx. 10-fold lower than that of classical insulin receptors, as assessed by inhibition of 1251-insulin binding by unlabelled hormone. It is concluded that the properties of insulin receptors, but not IGF receptors, are markedly affected by assembly as hybrid compared with classical structures, and that hybrids are more likely to be responsive to IGF-I than insulin under physiological conditions. hybrid structures (Soos and Siddle, 1989; Moxham et al., 1989; Soos et al., 1990) . Hybrids can also be generated in vitro from isolated a,f receptor halves (Treadway et al., 1989 (Treadway et al., , 1991 . Analogous hybrids have been described for other tyrosine kinase receptor families, including a and , PDGF receptors (Seifert et al., 1989; Heidaran et al., 1991) and EGF receptor/pl85neu (Wada et al., 1990; Qian et al., 1992) . There is as yet little information about the distribution and properties of insulin/IGF-I hybrid receptors, and it is therefore difficult to judge their functional significance. To facilitate further characterization, we have devised an immunoaffinity protocol for isolation of hybrid receptors from human placenta. We previously used free peptide to elute functionally active human and rat insulin receptors from an insulin-receptor-specific antipeptide monoclonal antibody (Ganderton et al., 1992) . We also recently reported the production of a panel of monoclonal antibodies to type I IGF receptors (Ullrich et al., 1986) together with an N-terminal tyrosine], was coupled to keyhole-limpet haemocyanin (KLH) at a weight ratio of 1:4 by using bis-diazotolidine (Basiri and Utiger, 1972; Briand et al., 1985) . Balb/c mice were injected subcutaneously with 0.1 mg of peptide-KLH conjugate at 6-weekly intervals (the first injection in Freund's complete adjuvant, and two subsequent injections in Freund's incomplete adjuvant). After a final intravenous boost of peptide-KLH conjugate together with WGA-Sepharose-purified type I IGF receptors from IGF-1R/3T3 cells (approx. 2 ,tg of receptor), spleen cells were fused with NSO/1 myeloma cells (Galfre and Milstein, 1981; Soos et al., 1986) . Antibodies were detected by reaction with receptor/1251-IGF-I complexes (Soos and Siddle, 1989; Soos et al., 1992) . Antibody-secreting cells were cloned at limiting dilution and amplified as ascites. Isotyping was performed by a haemagglutination assay (Serotec), using rabbit antisera specific for mouse IgGI, IgG2a, IgG2b, IgG3, IgA and IgM. Other monoclonal antibodies specific for the insulin receptor or type I IGF receptor were as described previously (Soos et al., 1986 Ganderton et al, 1992) . Antibodies were partially purified from ascites fluid by precipitation with 40% satd. (NH4)2SO4. Immunoadsorbents were prepared by covalent coupling of partially purified antibody to finely divided aminocellulose via a diazotization reaction (Hales and Woodhead, 1980) . For some experiments antibodies were further purified by hydroxyapatite chromatography (Stanker et al., 1985) and radioiodinated as previously described (Soos et al., 1984) .
Receptor preparations and 1251-ligand-binding assays Human placental microsomal membranes were prepared and solubilized as described (Soos et al., 1986; Soos and Siddle, 1989) and used in binding assays without further purification. IGF-1R/3T3 cells were solubilized and receptors partially purified by chromatography on WGA-Sepharose as described (Le Bon et al., 1986; Soos et al., 1990) . Binding of 1251-IGF-I or 1251-insulin (20000 c.p.m., counting efficiacy 75 %, approx. 50-100 pM) to solubilized receptors was measured after incubation for 16 h at 4°C as described (Soos et al., 1990) . Receptor-bound radioactivity was determined by precipitation with PEG 6000. Nonspecific binding was determined in the presence of 1 puM insulin or 0.1 ,sM IGF-I.
For immunodepletion before ligand-binding assays, receptors were incubated for 1 h at 4°C with anti-receptor antibody covalently coupled to cellulose. After centrifugation to remove supernatants were assayed for binding activity as described above. Co-precipitation of receptor/'251-ligand complexes was performed as described (Soos et al., 1986 (Soos et al., , 1990 . Receptors were preincubated with 125I-IGF-I or 1251-insulin for 16 h before addition of antibody for a further 1 h, and antibody-bound radioactivity was then determined by using a sheep anti-(mouse IgG) adsorbent.
Immunoblotting
Receptors isolated from detergent-solubilized IGF-lR/3T3 and NIH 3T3 HIR3.5 cells by WGA-Sepharose chromatography were subjected to SDS/PAGE, and proteins were blotted onto poly(vinylidene difluoride) membranes. After blocking in 50 mM Tris/HCl (pH 7.4)/100 mM NaCl (TBS) containing 5 % milk powder and 0.1 % Tween 20 for 16 h at 4°C, blots were incubated with anti-receptor antibody [1/200 dilution of 40 %0-(NH4)2SO4-precipitated ascites fluid in TBS/5 % milk powder/0.02 % Tween 20] for 1.5 h at 22 'C. After washing, the blots were then incubated with horseradish-peroxidase-coupled second antibody (1/2000 dilution) for 1 h, and developed by using the Amersham ECL system according to the manufacturer's instructions. An image was obtained by using the developed blot to expose Fuji RX NIF X-ray film for 15 s.
Two-site Immunoassay
Receptors were incubated with labelled anti-(insulin-receptor) antibody 83-14 (20000 c.p.m., approx. 25-50 pM) for 16 h at 4 'C in 100 ,ul of assay buffer (0.075 M Tris/HCl, pH 7.3 at room temperature, 0.03 M NaCl, 0.01 M glucose, 0.5 mM EDTA, 0.1 % BSA), before addition of 50 ,1 of immobilized antibody IGFR 17-69 or IR 83-7 for a further 1 h. The immunoadsorbents were then washed three times with ice-cold 0.1 M sodium phosphate buffer, pH 7.4, containing 0.1 % BSA and 0.1 % Triton X-100, and bound radioactivity was measured in a yradiation counter. Non-specific binding was determined by omitting the receptor preparation.
Immunoaffinity purification of receptors
Insulin receptors, type I IGF receptors and hybrid receptors were separated from each other by immunoaffinity purification using receptor-specific monoclonal antibodies (Scheme 1). Immunoadsorbents were prepared by coupling partially purified antibody to aminocellulose (100 ltg of antibody/mg of cellulose) as described previously (Hales and Woodhead, 1980; Soos et al., 1986) . Human placental membranes were prepared and solubilized with 2 % (w/v) Triton X-100 as described by FujitaYamaguchi et al. (1983) . Solubilized membranes (5 ml) were diluted with an equal volume of buffer containing protease inhibitors (0.075 M Tris/HCl, pH 7.3, 0.03 M NaCl, 0.5 mM EDTA, 0.1 % BSA, 0.02 mM phenylmethanesulphonyl fluoride, 0.4 mg/ml benzamidine, 1 ,ug/ml pepstatin, 1 ,ug/ml antipain, 1 ,ug/ml leupeptin, 200 kallikrein-inhibitor units/ml aproptinin, 0.2 mM bacitracin), and mixed for 1 h at 4 'C with 5 mg of appropriate immunoadsorbent (Scheme 1). Immunoadsorbents were then pelleted by centrifugation (5 min in a microcentrifuge, 4 'C), and the supernatant was taken for further purification of residual receptors using 0.5 mg of the appropriate immobilized anti-peptide antibody (Scheme 1). After RESULTS Production and characterization of antibody 1-2
To produce an antibody for use in purification of type I and hybrid IGF receptors, mice were immunized with a peptide corresponding to the C-terminal sequence of the IGF receptor ,-subunit. Five fusions were performed, two of which yielded six positive wells on initial screening. A single hybridoma was cloned, secreting an IgGl monoclonal antibody designated IGFR 1-2. The screening assay employing receptor/'251-IGF-I complexes ensured that only antibodies reacting with native receptor were detected, and it was confirmed that antibody IGFR 1-2 also bound unoccupied receptors (Table 1 ). The efficiency of reaction of antibody 1-2 was less than that of previously obtained monoclonal antibodies to IGF receptors suggesting that 1-2 was of relatively low affinity. In spite of this low affinity, antibody 1-2 reacted well with denatured receptor ,-subunit on immunoblots ( Figure 1 ). The reaction of antibody 1-2 with the type I IGF receptor was highly specific. There was no detectable reaction with human insulin receptor from NIH 3T3 HIR3.5 cells on immunoblots (Figure 1 ) or in a '251-insulin/receptor co-precipitation assay (results not shown). The anti-peptide antibody (CT-1) (Ganderton et al., 1992) was specific for the insulin receptor under the same conditions (Figure 1 ). Antibody 1-2 precipitated just three polypeptides, corresponding to the a-and f8-subunits of the receptor and unprocessed proreceptor, from metabolically labelled IGF-1R/3T3 cells . Species crossreaction was investigated using co-precipitation assays with 1251_ IGF-I bound to receptors from Rat 1 fibroblasts. In contrast with all monoclonal antibodies to IGF receptor previously described (Kull et al., 1983; Soos et al., 1992) , antibody 1-2 reacted equally with rat and human receptors (results not shown). (93) 14 (90) 56 (97) 7780 (0) 62 (98) 13 (90) 1840 (0) 15 (100) antibodies react with the hybrid subfraction of IGF receptors in human placenta (Soos and Siddle, 1989) . We therefore further investigated antibodies for various epitopes on the type I IGF receptor bound > 90 % of receptors from both sources. As previously described (Soos and Siddle, 1989) , anti-insulin-receptor antibodies (e.g. 83-14) reacted with hybrid receptors representing approx. 75 % of IGF-I binding in placental extracts, but were unreactive with type I IGF receptors in IGF-1R/3T3 cells. The subfractions of receptor which were unreactive with the anti-IGF-receptor antibody 24-55 or the anti-insulin-receptor antibody 83-14 were subjected to a second depletion. Receptor which was not depleted by a first incubation with antibody 24-55 was almost fully removed by subsequent incubation with either the anti-insulin-receptor antibody 83-14 or the anti-IGF-receptor antibody 24-60 (Table 2) , and therefore represents hybrids. Only a small fraction of these receptors was removed by a second incubation with antibody 24-55 itself. Conversely, material not depleted by a first incubation with anti-insulin-receptor antibody 83-14 was efficiently removed by subsequent incubation with both the anti-IGF-receptor antibodies 24-55 and 24-60, but not by a second incubation with antibody 83-14 itself (Table 2) , as expected for classical type I IGF receptors. Our interpretation of these results is that antibody 24-55 reacts well with classical receptors but poorly with hybrids, whereas antibody 24-60 reacts with all IGF-I receptors.
Purification of receptors
Two-step immunoaffinity purification schemes were developed to isolate the different receptors present in solubilized placental membranes (Scheme 1). In each case, preparations were first depleted of unwanted receptors by using an appropriate immobilized antibody. Required receptors remaining in the supernatant were then purified by binding to a second (antipeptide) antibody, followed by specific elution with free peptide.
To obtain hybrid receptors, classical type I IGF receptors were first removed by using immobilized antibody IGFR 24-55, under conditions which left insulin receptors and,most of the hybrids in solution. Hybrids were then isolated by using immobilized antibody IGFR 1-2. This gave a 14% yield of IGF-I binding activity, which was estimated to be a 22% yield of hybrid receptors. Classical type I IGF receptors were also isolated by using immobilized IGFR 1-2, but after first removing hybrid and insulin receptors with immobilized IR 83-14. This gave an 11 0% yield of IGF-I binding activity, which was estimated to be 30 % of the type I IGF receptors. Insulin receptors were isolated by using immobilized antibody CT-I (Ganderton et al., 1992) , after removal of hybrid and classical type I IGF receptors with IGFR 24-60. The yield of insulin receptors was 42 %.
It was confirmed that purified hybrid receptors were essentially free of classical insulin receptors and type I IGF receptors. Thus the binding activity of the hybrid preparation for both 1251-IGF-I and 1251-insulin was removed (> 90%) by immunodepletion with either immobilized antibody IGFR 24-60 or antibody IR 83-14 (Table 3) . These antibodies are known to be specific for the respective receptors (Soos et al., 1990 , although both epitopes must also be accessible in hybrids. In contrast, ligand-binding activity of purified type I receptors was significantly depleted only by antibody IGFR 24-60, and that of insulin receptors only by antibody IR 83-14. This was the case not only for binding of each ligand to its own receptor (Table 3) , but also for the very low level of binding of each radioligand to the heterologous receptor. Thus, for the insulin-receptor preparation, 90 % of the 1251-IGF-I binding activity was removed by IR 83-14 but only 20% by IGFR 24-60, whereas for the type I receptor preparation 98 % of the '251-insulin-binding activity was removed by IGFR 24-60, but only 15 % by IR 83-14 (results not shown).
Ligand-binding studies
Purified hybrid receptors readily bound 125I-IGF-I, as previously demonstrated with intact cells and crude cell lysates (Soos and Siddle, 1989; Soos et al., 1990) . The concentration of unlabelled IGF-I for half-maximal inhibition of 125I-IGF-I binding was 0.1-0.2 nM for hybrids and 0.05-0.1 nM for type I receptors ( Figure 2a , Table 4 Chang et al., 1975 (Figure 2a and 2d, Table 4) . Moreover, the IGF-I/'251-insulin displacement curve for hybrids receptor antibody could be used in place of 1251-insulin in this kind ofassay. Hybrid receptors were incubated with 1251-antibody 83-14 and then with immobilized anti-IGF-receptor antibody 17-69 or anti-insulin receptor antibody 83-7. Both immobilized was more shallow than other displacement curves, suggesting antibodies bound similar amounts of '251-antibody 83-14, as that IGF-I may have been binding to two sites with different expected (Table 6 ). This result confirms that insulin-receptoraffinities. The possibility that high-affinity binding of IGF-I to specific and IGF-receptor-specific antibodies can bind simulthe IGF half-receptor indirectly influences the affinity of the taneously to hybrid receptors, a property which could form the insulin half-receptor therefore cannot be ruled out.
basis for a quantitative assay of hybrids in tissue extracts.
When insulin-binding assays were carried out using the same Effect of disulphide reduction on ligand binding to hybrid receptor concentrations and assay format as in Table 6 , the of 83-14. However, if receptor concentrations are normalized for ligand binding to the purified receptors was determined before equal binding of 83-14, insulin binding to hybrids is < 10 % of and after treatment with dithiothreitol, under conditions known that to classical receptors, consistent with the calculated to reduce a-a disulphides (Table 5) . As previously reported, difference in relative affinity for insulin.
binding of 1251-insulin to insulin receptors was substantially
When crude placental extracts were incubated with 12511 decreased after disulphide reduction (to 27 +2% of control antibody 83-14, the radioactivity bound by immobilized antivalues; mean+ S.D. for three independent experiments). How-IGF-receptor antibody 17-69 was approx. 10 % of that bound by ever, binding of I251-insulin to hybrids actually increased after anti-insulin-receptor antibody 83-7 (Table 6 ). Allowing for reduction (to 177 + 18 % of controls; n = 3), indicating that uncertainty as to whether classical receptors bind one or two hybrids have an even lower affinity for insulin than isolated half-molecules of 83-14, these data suggest that hybrids contain receptors. By contrast, binding of 125I-IGF-I to type I receptors 10-20 % of the tissue insulin receptor halves. On the other hand, was little affected by reduction (105 + 33 % of controls; n = 3), based on the reactivity of IGF-I binding sites with anti-insulinwhereas binding to hybrids was slightly decreased (73 + 6 % of receptor antibodies, hybrids appeared to account for 50-70 % of controls; n = 3). Thus the state of assembly of type I receptors the placental type I receptor halves (Soos and Siddle, 1989) . It has only a minor influence on their affinity for IGF-I.
has been estimated that the total concentration of IGF-I receptors in human placenta is approx. 10 % of the insulin receptor for IGF-I as for insulin in solubilized membranes.
IGF-I binding sites reactive with insulin-receptor-specific antibodies (Soos and Siddle, .1989; Soos et al.,. 1990 ). This-is applicable as an assay for hybrids under conditions where insulin receptors are in excess, and therefore hybrids account for a The physiological role of hybrid insulin/IGF-I receptors remains significant fraction of total IGF binding. However, it would be unclear. Although it might be expected that hybrids would bind difficult to detect hybrids by this means when type I IGF both insulin and IGF-I, there are indications that they respond receptors were in large excess and the fraction of IGF-binding more readily to IGF-I than to insulin, at least in terms of sites contributed by hybrids was small. Because hybrids bind autophosphorylation (Moxham et al., 1989; insulin with relatively low affinity, they cannot be quantified as Jacobs, 1992) . We therefore devised a method for immunoaffinity a fraction of'25I-insulin binding reactive with anti-IGF-I receptor purification of hybrid receptors in order to study their properties antibodies. We therefore tested whether 1251-labelled anti-insulinin vitro without interference from other receptor types.
Several anti-IGF-receptor antibodies were identified which reacted much less efficiently with hybrid receptors from placenta than with type I receptors from transfected fibroblasts ( Table 1) . Some of these antibodies recognized epitopes in the region 440-586 of the type I receptor a-subunit , and these epitopes must depend on local conformations or intersubunit contacts which differ between hybrid and classical IGF receptors. By using one of these antibodies, IGFR 24-55, it was possible selectively to deplete solubilized placental membranes of classical type I receptors without removing the majority of hybrid receptors. This permitted the purification of residual hybrids by using the IGF-receptor-specific anti-peptide monoclonal antibody, IGFR 1-2. This antibody was directed against the C-terminus of the receptor f8-subunit, analogously to the previously described anti-insulin-receptor antibody CT-1 (Ganderton et al., 1992) . Antibody 1-2 appeared to be ofrelatively low avidity, a property which made it particularly suitable for use in immunoaffinity purification because of the ease of recovering dissociated receptor in the presence of excess free peptide antigen. Insulin receptors and type I IGF receptors were also purified from placenta by immunoaffinity techniques and peptide elution under mild conditions (Scheme 1). Previous methods for purifying type I IGF receptors, using IGF-I-Sepharose (Maly and Luthi, 1986) or specific monoclonal antibodies (Le Bon et al., 1986) , involved potentially denaturing conditions for elution of bound receptor.
It was clearly shown that purified hybrids bound IGF-I, but not insulin, with high affinity. The affinity of hybrids for IGF-I, as indicated by the IC50 for displacement of '25I-IGF-I, was similar to that of classical type I receptors. However, the affinity of hybrids for insulin was approx. 10-fold lower than that of classical insulin receptors, and 20-fold lower than the affinity of hybrids for IGF-I. The concentration of insulin required to inhibit binding of 1251-insulin to hybrids (IC50 approx. 4 nM) was considerably lower than that required to inhibit binding of 1251_ IGF-I (IC50 approx. 100 nM), confirming that insulin is indeed binding to the insulin half-receptor within a hybrid, albeit with relatively low affinity. Hybrids reacted well with all available anti-insulin-receptor antibodies, but not all anti-IGF-receptor antibodies, implying that conformational changes responsible for altered ligand binding and immunoreactivity of hybrid compared with classical receptors are distinct and relatively localized within the receptor structure.
These observations on hybrid receptors extend previous studies indicating that ligand-binding affinity of the insulin half-receptor is dramatically dependent on its state of assembly. Classical insulin-receptor heterotetramers bind only a single molecule of insulin with high affinity Shafer, 1983, 1984) , and isolated insulin half-receptors have 10-fold lower affinity for insulin that do intact heterotetramers (Boni-Schnetzler et al., 1987; Sweet et al., 1987) . When hybrids were subjected to disulphide reduction to release the individual half-receptors, 125I_ insulin binding increased 1.8-fold (Table 5 ), indicating that the affinity for insulin of intact hybrids is even less than that of isolated half-receptors. Previous data suggesting that hybrids reconstituted in vitro from isolated receptor halves bound comparable amounts of 1251-insulin to classical insulin receptors (Treadway et al., 1989) may in part reflect the use of higher ligand concentrations, which would diminish the effects ofaffinity differences. It may also be that hybrids assembled in vitro differ in subtle respects from naturally occurring hybrids, perhaps in terms of incomplete formation of inter-subunit disulphides.
It is generally assumed that receptor-binding interactions of insulin are entirely within a single a-subunit. On this model, binding affinity depends on conformation as influenced by an adjacent a-subunit: combination of two unoccupied insulin receptor a-subunits is essential for high-affinity binding, and single occupancy within a classical heterotetramer is proposed to decrease the affinity of the unoccupied a-subunit by negatively co-operative interactions (De Meyts et al., 1976; Pang and Shafer, 1983) . Combination of an IGF half-receptor with the insulin half-receptor in a hybrid may similarly impose a conformation with low affinity for insulin. It will be interesting to test whether hybrids display negative co-operativity in terms of effects of IGF on dissociation of insulin, and vice versa. Equilibrium binding studies did not clearly show whether one ligand can affect binding of the other by 'trans' co-operative interactions, as opposed to direct 'cis' competition, although there was some indication that insulin binding was decreased by low concentrations of IGF (Figure 2d ). An alternative model for different affinity states of the insulin receptor is suggested by recent work on the growth-hormone receptor, in which it has been shown that a single growthhormone molecule forms a high-affinity complex by asymmetric interaction with both halves of a receptor dimer (Cunningham et al., 1991) . In a similar way, 'trans' interactions with both asubunits of a heterotetrameric insulin receptor may contribute to high-affinity ligand binding and conformational changes involved in receptor activation. This proposal would be consistent with studies of photoaffinity cross-linking of insulin, which have shown that different parts of the insulin molecule contact distinct regions of the receptor (Yip et al., 1988; Wedekind et al., 1989; Fabry et al., 1992) . On this model, the low affinity of hybrids for insulin might reflect the absence of appropriate 'trans' interactions necessary to increase the affinity above that observed with isolated half-receptors. It should be possible to use hybrid receptors, together with photo-activatable insulin analogues, to probe the relative proximity of different parts of the bound ligand to the two receptor halves.
Whatever the molecular basis for the various affinity states of insulin receptors, it is clear that IGF receptors behave differently. Hybrid and classical type I receptors displayed similar affinity for IGF-I (Table 4) , and, in agreement with a previous study (Feltz et al., 1988) this was little affected by reduction of inter-subunit disulphides (Table 5 ). Most workers report linear Scatchard plots for IGF-I binding to type 1 receptors from diverse sources, suggesting there is no co-operativity, although there are conflicting reports as to whether the receptors bind one or two molecules of IGF with high affinity (Feltz et al., 1988; Tollefsen and Thompson, 1988 ).
Other investigators have described 'atypical' receptors which bind both IGF-I and insulin with relatively high affinity (Jonas, 1988) . Atypical receptors reportedly display specificity in their reaction with anti-receptor antibodies, in contrast with hybrids, which react with both anti-insulin-receptor and anti-IGF-receptor antibodies. To confirm that hybrid and atypical receptors are distinct entities, we looked for 'atypical' properties in immunoaffinity-purified type I IGF receptors and insulin receptors which were free of hybrids. Purified type I receptors bound IGF-I with high affinity as expected, but there was a considerable discrepancy between the concentrations of insulin required to inhibit binding of 125I-IGF-I and 1251-insulin (IC50 300 nM and 4 nM respectively, Table 5 ). This indicates the presence of an atypical subfraction of IGF receptors with anomalously high affinity for insulin, as described previously in several cell types (Hintz et al., 1984; Misra et al., 1986; Burant et al., 1987; Waldbillig and Chader, 1988; Milazzo et al., 1992) .
With purified insulin receptors, IGF-I was more effective in competing binding of '25I-IGF-I than that of 1251-insulin (IC50 3 nM and 50 mM respectively; Table 5 ). Atypical insulin recep-tors defined by similar criteria have been described previously in placenta (Jonas et al., 1989) , and in IM-9 lymphocytes (Jonas and Cox, 1990) . The structural basis of atypical receptors is unclear, although a subfraction of insulin receptors displaying atypical binding kinetics was seen in transfected cells expressing cloned receptor cDNA . It may be that IGFreceptor cDNA can similarly give rise to both normal and atypical receptors in transfected cells, and we now believe that most of the relatively high-affinity insulin binding to solubilized receptors from transfected IGF-IR/3T3 cells (Soos et al., 1990) is to atypical rather than hybrid IGF receptors.
In summary, we have purified hybrid insulin/IGF receptors which are distinct from previously described atypical receptors, and demonstrated that the properties of insulin receptors, but not IGF receptors, are markedly affected by assembly as hybrid compared with classical structures. It is concluded that hybrids are more likely to be responsive to IGF-I than to insulin under physiological conditions, but a number of questions regarding the biological importance of hybrid receptors remain to be answered. The purification procedures described here will allow examination of hybrid receptor activation by insulin and IGF-I, and the availability of a specific two-site immunoassay will permit investigation of the tissue distribution of hybrids.
